{{Rsnum
|rsid=5277
|Gene=PTGS2
|Chromosome=1
|position=186679065
|Orientation=minus
|GMAF=0.09458
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=PTGS2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 4.8 | 30.2 | 65.1
| HCB | 0.0 | 4.4 | 95.6
| JPT | 0.0 | 11.4 | 88.6
| YRI | 0.0 | 0.0 | 100.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 4.4 | 95.6
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

[[rs5277]] is a SNP in the prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) [[PTGS2]] gene, also known as COX-2.

A meta-analysis involving nine studies with 6,968 [[breast cancer]] cases and 9,126 controls found just a borderline significant increased risk (of breast cancer) in a recessive model (odds ratio 1.217, CI: 0.958-1.547, p = 0.107).{{PMID|20033767}}

{{PMID Auto
|PMID=19820421
|Title=The Effect of Genetic Polymorphisms of Cyclooxygenase 2 on Acute Pancreatitis in Turkey
}}

{{PMID Auto
|PMID=19755647
|Title=Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial
|OA=1
}}

{{PMID Auto
|PMID=20711808
|Title=Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists
|OA=1
}}

{{PMID Auto
|PMID=21705955
|Title=Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility
}}

{{PMID|17171651}} Cyclooxygenase-2 polymorphisms in Parkinson's disease.

{{PMID|17214885|OA=1
}} A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study.

{{PMID|17404026}} Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population.

{{PMID|17999989}} Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.

{{PMID|18085997}} Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance.

{{PMID|18768181|OA=1
}} Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study.

{{PMID|18992148|OA=1
}} Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study.

{{PMID|19223558|OA=1
}} Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.

{{PMID|19318492|OA=1
}} Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk.

{{PMID|19437564|OA=1
}} No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk.

{{PMID|19661089|OA=1
}} Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.

{{PMID Auto
|PMID=22464751
|Title=SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors.
}}

{{PMID Auto
|PMID=23029430
|Title=Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinoma.
|OA=1
}}

{{PMID Auto
|PMID=24870748
|Title=The Prostaglandin Synthase 2/cyclooxygenase 2 (PTGS2/ COX2) rs5277 Polymorphism Does not Influence Risk of Colorectal Cancer in an Iranian Population
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}